What does Acomplia do?
Acomplia acts by selectively blocking CB1 receptors found in the brain and in peripheral organs important in glucose and lipid (or fat) metabolism, including adipose tissue, the liver, gastrointestinal tract and muscle2. Acomplia switches off the same brain circuits that make people hungry when they smoke cannabis.
Is rimonabant a cannabinoid?
Abstract. Rimonabant is a potent and selective cannabinoid CB1 receptor antagonist widely used in animal and clinical studies.
Why was rimonabant withdrawal from the market?
The anti-obesity medication rimonabant, an antagonist of cannabinoid type-1 (CB1) receptor, was withdrawn from the market because of adverse psychiatric side effects, including a negative affective state.
How does rimonabant work?
Rimonabant is the first developed drug which acts as a selective antagonist of the CB1 receptor. It acts centrally to suppress food intake and peripherally in adipose tissue, liver, muscles and the GI tract to regulate lipid and glucose metabolism.
Is Rimonabant FDA approved?
Although available in Europe since 2006 for use as an adjunct to diet and exercise for obese or overweight patients with associated risk factors, Acomplia failed to secure FDA approval in the US.
Is Lorcaserin a controlled substance?
On 7 May 2013, the US Drug Enforcement Administration classified lorcaserin as a Schedule IV drug under the Controlled Substances Act.
What does rimonabant do at the synapse?
Rimonabant antagonises at the CB1 receptor. The end result is an increase in release of inhibitory neurotransmitters, reduced stimulatory neuronal activity and satiety.
Is CBD an antagonist?
Cannabidiol has been reported to act as an antagonist at cannabinoid CB1 receptors. We hypothesized that cannabidiol would inhibit cannabinoid agonist activity through negative allosteric modulation of CB1 receptors.